Organox Limited appears in FDA device records as the applicant for the OrganOx metra System, filed under PMA number P200035 with product code QQK. The supplied record sample contains two approval decisions: the original application, decided 9 December 2021, and supplement S038, decided 9 October 2026. The collection counts show two approvals across two linked records, all on the PMA pathway, and no recall records in the supplied sample. Those figures describe the supplied filings as of the snapshot date, not company sales, total portfolio or safety performance. [1][2]

Documented product and intended use

The FDA record describes the OrganOx metra System as a normothermic machine perfusion system for the preservation of donor livers prior to transplantation, assigned device class 3 and product code QQK, with the Gastroenterology, Urology advisory committee listed. The approval statement recorded with the original application states that the device is transportable and intended to sustain donor livers destined for transplantation in a functioning state for a total preservation time of up to 12 hours. [2][5]

OrganOx's own product page describes the metra as a normothermic machine perfusion platform for liver transplant procedures and states that the platform extends organ preservation time. A separate company page on how the device works states that the donor liver is continuously perfused with oxygenated blood, medications and nutrients at normal body temperature and near physiological pressures and flows, and describes the device as transportable and battery powered with a graphical user interface. These are company-published descriptions. [6][8]

Regulatory history in the supplied filings

The original PMA, P200035, was received on 15 July 2020 and approved on 9 December 2021, with a Federal Register notice date of 17 December 2021 and docket number 21M-1317. The FDA summary of safety and effectiveness data lists the same PMA number, the trade name OrganOx metra System, generic name organ preservation system, and an FDA notice of approval dated 12/9/2021. [2][5]

Supplement S038 was received on 24 April 2026 and approved on 9 October 2026 under the normal 180-day track, with supplement reason recorded as change design/components/specifications/material. The approval statement describes changing the supplier of the Blood Reservoir, minor manufacturing process changes for the filter materials, and increasing the wall thickness of five tubing segments in the blood circulation loop of Disposable Set (D0146/D0146-US). [1]

Applicant identity and published company material

FDA records name Organox Limited as the applicant, with a filing address at Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford. That address appears in the regulatory filing and is not treated here as a verified headquarters. The public information does not identify a parent company, brand owner or corporate group for Organox Limited, so ownership remains unknown. [1][2]

OrganOx's website footer states that the metra is a CE marked device in the EU and an FDA approved device in the USA, and identifies OrganOx Limited as registered in England and Wales with registration number 06557113. A U.S. patient brochure published under the P200035 document set describes the metra as a normothermic perfusion system for preserving livers before transplantation and is addressed to patients on the U.S. liver transplant waiting list. [8][10]